Originally Published MX January/February 2005

BUSINESS NEWS

The results of a six-month safety and angiographic follow-up study of patients implanted with a new bioabsorbable coronary drug-eluting stent were reported last November at the annual scientific sessions of the American Heart Association (AHA; Dallas), in New Orleans.

The BioMatrix bioabsorbable coronary stent by Biosensors International. (click to enlarge)

The study was sponsored by Biosensors International Pte Ltd. (Singapore), manufacturer of the BioMatrix stent used in the clinical trials. In contrast to currently approved coronary drug-eluting stents, which use a permanent polymer coating, the BioMatrix stent features a bioabsorbable polymer coating that dissolves during drug release. The resulting solution is made up of all-natural by-products that are metabolized and excreted by the body as carbon dioxide and water.